Skip to main content
. 2020 Aug 31;10:14270. doi: 10.1038/s41598-020-64991-5

Table 1.

Demographics and disease characteristics of patients with rheumatoid arthritis at baseline.

MTX plus rhTNFR:Fc52(n = 32) MTX plus rhTNFR:Fc24(n = 30) MTX (n = 26) Pa MTX plus rhTNFR:Fc(n = 62) Pb
Female, n (%) 28 (87.50) 22 (73.33) 22 (84.62) 0.32 50 (80.65)
Age, years 40.78 (13.35) 44.67 (11.73) 43.31 (9.93) 0.43 42.66 (12.64)
Duration of RA, years 10.73 (9.92) 7.63 (9.14) 7.10 (7.66) 0.22 9.23 (9.60)
Duration of morning stiffness, min 91.29 (92.47) 111.33 (87.05) 101.15 (136.55) 0.38 101.15 (89.67) 0.36
Rest pain VAS 62.66 (23.83) 63.83 (16.38) 49.27 (25.32) 0.03 63.23 (20.41) 0.02
HAQ 1.62 (0.76) 1.52 (0.56) 1.20 (0.59) 0.04 1.57 (0.66) 0.01
Physician VAS 64.19 (15.66) 65.97 (14.34) 57.69 (17.68) 0.18 65.07 (14.93) 0.07
Patient VAS 64.41 (16.92) 67.63 (16.53) 60.38 (18.54) 0.30 65.97 (16.67) 0.24
Tender joint count (68) 19.06 (13.30) 17.67 (10.77) 13.96 (7.15) 0.21 18.39 (12.07) 0.08
Swollen joint count (66) 11.59 (9.10) 11.60 (6.56) 10.92 (6.74) 0.60 11.60 (7.91) 0.41
ESR, mm/h 51.59 (21.94) 56.13 (29.20) 63.00 (35.17) 0.61 53.79 (25.60) 0.37
CRP, mg/L 3.16 (2.81) 3.97 (3.17) 6.12 (4.15) 0.20 3.55 (2.99) <0.01
mTSS 14.76 (19.65) 10.17 (13.37) 13.38 (11.00) 0.36 12.68 (17.10) 0.30
Joint erosion 6.86 (9.37) 5.08 (7.40) 6.52 (5.90) 0.27 6.06 (8.50) 0.27
Joint space narrowing 7.90 (10.86) 5.08 (6.59) 6.86 (6.38) 0.64 6.62 (9.20) 0.44
DAS28 4.94 (0.82) 5.15 (0.82) 4.88 (0.91) 0.44 5.05 (0.82) 0.40
CDAI 33.10 (11.61) 35.56 (11.52) 29.65 (11.45) 0.08 34.29 (11.53) 0.04
SDAI 36.26 (12.49) 39.40 (12.56) 35.77 (13.21) 0.35 37.78 (12.52) 0.57

All values are mean (SD) unless otherwise stated. RA, rheumatoid arthritis; VAS, visual analogue score; HAQ, health assessment questionnaire; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; mTSS, van de Heijde modified Total Sharp Score; DAS28, disease activity score 28; CDAI, clinical disease activity index; SDAI, simplified disease activity index. Pa: comparison among three groups; Pb: comparison between rhTNFR:Fc pooled groups and methotrexate group.